Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
7.50
-0.24 (-3.10%)
Jun 29, 2026, 12:17 PM EDT - Market open
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Entrada Therapeutics stock have an average target of 18.75, with a low estimate of 10 and a high estimate of 25. The average target predicts an increase of 150.00% from the current stock price of 7.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Entrada Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 8 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Buy Maintains $20 → $17 | Buy | Maintains | $20 → $17 | +126.67% | Jun 5, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $23 | Buy | Reiterates | $23 | +206.67% | Jun 3, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $6.64 → $10 | Buy | Reiterates | $6.64 → $10 | +33.33% | Jun 3, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | May 8, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 7, 2026 |
Financial Forecast
Revenue This Year
14.99M
from 25.42M
Decreased by -41.04%
Revenue Next Year
29.81M
from 14.99M
Increased by 98.87%
EPS This Year
-3.79
from -3.47
EPS Next Year
-3.26
from -3.79
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 60.0M | 85.0M | |
| Avg | 15.0M | 29.8M | |
| Low | 875,000 | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 136.0% | 467.1% | |
| Avg | -41.0% | 98.9% | |
| Low | -96.6% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -2.68 | -2.20 | |
| Avg | -3.79 | -3.26 | |
| Low | -4.49 | -5.08 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.